Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism

Current Topics in Medicinal Chemistry

Volumn 14, Issue 11, 2014, Pages 1348-1355

  Sevrioukova, Irina F ^a   Poulos, Thomas L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crystal structure; CYP3A4; Inhibitor design; Ligand binding; Pharmacophore; Ritonavir analogues

Indexed keywords

ABT 538 DEAZA RITONAVIR; COBICISTAT; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HYDROXYL GROUP; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RITONAVIR; THIAZOLE; UNCLASSIFIED DRUG; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR;

CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG MECHANISM; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROXYLATION; IC 50; LIGAND BINDING; MUTAGENESIS; PHARMACOPHORE; REVIEW; X RAY CRYSTALLOGRAPHY; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; METABOLISM; STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RITONAVIR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903709977     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140506120647     Document Type: Review

References (22)

1. Guengerich, F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 1-17.
2. Sevrioukova, I.F.; Poulos, T.L. Understanding the mechanism of cytochrome P450 3A4: Recent advances and remaining problems. Dalton Trans., 2013, 42(9), 3116-3126.
3. Kempf, D.J.; Marsh, K.C.; Kumar, G.; Rodrigues, A.D.; Denissen, J.F.; McDonald, E.; Kukulka, M.J.; Hsu, A.; Granneman, G.R.; Baroldi, P.A.; Sun, E.; Pizzuti, D.; Plattner, J.J.; Norbeck, D.W.; Leonard, J.M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother., 1997, 41(3), 654-660.
4. Xu, L.; Liu, H.; Murray, B.; Callebaut, C.; Lee, M.S.; Hong, A.; Strickley, R.G.; Tsai, L.K.; Stray, K.M.; Wang, Y.; Rhodes, G.R.; Desai, M.C. Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med. Chem. Lett., 2010, 1, 209-213.
5. Kempf, D.J.; Marsh, K.C.; Denissen, J.F.; McDonald, E.; Vasa-vanonda, S.; Flentge, C.A.; Green, B.E.; Fino, L.; Park, C.H.; Kong, X.P.; Wideburg, N.E.; Saldivar, A.; Ruiz, L.; Kati, W.M.; Sham, H.L.; Robins, T.; Stewart, K.D.; Hsu, A.; Plattner, J.J.; Leonard, J.M.; Norbeck, D.W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA, 1995, 92(7), 2484-2488.
6. Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ri-tonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug. Metab. Dispos., 1998, 26(6), 552-561.
7. von Moltke, L.L.; Durol, A.L.; Duan, S.X.; Greenblatt, D.J. Potent mechanism-based inhibition of human CYP3A in vitro by am-prenavir and ritonavir: comparison with ketoconazole. Eur. J. Clin. Pharmacol., 2000, 56(3), 259-261.
8. Ernest, C.S., 2nd; Hall, S. D.; Jones, D.R. Mechanism-based inac-tivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther., 2005, 312(2), 583-591.
9. Lin, H.L.; D'Agostino, J.; Kenaan, C.; Calinski, D.; Hollenberg, P.F. The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. Drug Metab. Dispos., 2013, 41(10), 1813-1824.
10. Li, F.; Lu, J.; Ma, X. Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem. Res. Toxicol., 2011, 24(12), 2109-2114.
11. VandenBrink, B.M.; Hengel, S.M.; Rock, D.A.; Wienkers, L.C.; Goodlett, D.R.; Kunze, K.L. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. In: Book of Abstracts of the 18th International Conference on Cytochrome P450 Biochemistry, Biophysics, Biotechnology: 2013 June18-22; Seattle, Washington, USA; p. 176.
12. Sekiguchi, N.; Higashida, A.; Kato, M.; Nabuchi, Y.; Mitsui, T.; Takanashi, K.; Aso, Y.; Ishigai, M. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab. Phar-macokinet., 2009, 24(6), 500-510.
13. Iribarne, C.; Berthou, F.; Carlhant, D.; Dreano, Y.; Picart, D.; Lo-hezic, F.; Riche, C. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug. Metab. Dispos., 1998, 26(3), 257-260.
14. Eagling, V.A.; Back, D.J.; Barry, M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol., 1997, 44(2), 190-194.
15. Kumar, G.N.; Rodrigues, A.D.; Buko, A.M.; Denissen, J.F. Cyto-chrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther., 1996, 277(1), 423-431.
16. Zalma, A.; von Moltke, L.L.; Granda, B.W.; Harmatz, J.S.; Shader, R.I.; Greenblatt, D.J. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol. Psychiatry, 2000, 47(7), 655-661.
17. Sevrioukova, I.F.; Poulos, T.L. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc. Natl. Acad. Sci. U S A, 2010, 107(43), 18422-18427.
18. Sevrioukova, I.F.; Poulos, T.L. Interaction of human cytochrome P4503A4 with ritonavir analogs. Arch. Biochem. Biophys., 2012, 520(2), 108-116.
19. Sevrioukova, I.F.; Poulos, T.L. Pyridine-substituted desoxyrito-navir is a more potent cytochrome P450 3A4 inhibitor than rito-navir. J. Med. Chem., 2013, 56(9), 3733-3741.
20. Mathias, A.A.; German, P.; Murray, B.P.; Wei, L.; Jain, A.; West, S.; Warren, D.; Hui, J.; Kearney, B.P. Pharmacokinetics and phar-macodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther., 2010, 87(10), 322-329.
21. Sevrioukova, I.F.; Poulos, T.L. Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues. Biochemistry, 2013, 52(26), 4474-4481.
22. Flentge, C.A.; Randolph, J.T.; Huang, P.P.; Klein, L.L.; Marsh, K.C.; Harlan, J.E.; Kempf, D.J. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs. Bioorg. Med. Chem. Lett., 2009, 19(18), 5444-5448.